The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVRP.L Share News (VRP)

  • There is currently no data for VRP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS SUMMARY: Airlines Hit As UK Quarantine List Grows

Fri, 14th Aug 2020 10:56

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Friday.

----------

FTSE 100 - LOSERS

----------

International Consolidated Airlines, down 6.5%. Shares in the British Airways parent were lower after the UK added France to its 14-day quarantine list. People arriving in the UK after 0400 BST on Saturday will be required to spend 14 days in self-isolation due to rising numbers of coronavirus cases in France. The conditions will also apply to travellers returning to the UK from the Netherlands, Monaco, Malta, Turks & Caicos and Aruba. The move, which applies throughout the UK, comes after Prime Minister Boris Johnson promised to be "absolutely ruthless" in decisions about imposing quarantine restrictions on countries. "The problem for the airlines is that people's desire for a break in the sun may be outweighed by their fear of the logistical challenges of holing up for two weeks when they get back, with decisions on which countries to add to the quarantine list often coming at short notice. This decision will feel particularly painful as it comes at the height of the UK holiday season and the question now becomes just how long the likes of EasyJet, Ryanair and British Airways-owner IAG can continue under these conditions," AJ Bell's Russ Mould commented.

----------

FTSE 250 - WINNERS

----------

Rank Group, up 3.5%. Shares in the gambling company were higher ahead of the reopening of casinos in the UK this weekend, as lockdown restrictions ease further. Under social distancing rules, casinos in the UK will reopen on Saturday for the first time since the lockdown was imposed. Rank Group owns Grosvenor Casinos, the largest UK casino operator with 52 casinos nationwide and Mecca Bingo, the UK's leading bingo operator.

----------

FTSE 250 - LOSERS

----------

easyJet, down 7.5%, Tui, down 5.8%. The travel stocks were dealt a blow by the UK government decision to add France to the quarantine list. "With France being added to the quarantine list for the UK, travel & leisure is under pressure. Shares in IAG, Ryanair, Tui and EasyJet were all sharply lower as the move will force a large swathe of cancellations right at the peak of the summer holiday season for one of the largest markets for UK tourists. Half a million Brits are thought to be in France right now," said Markets.com analyst Neil Wilson. Elsewhere, Irish carrier Ryanair Holdings was down 4.9% and Dart Group, which owns the Jet2 airline, was down 9.5%.

----------

WH Smith, down 5.5%. Shares in the books, magazines and confectionery retailer were also lower as part of the UK's new quarantine travel rules. WH Smith generates a substantial amount of its revenue from stores in airports and train stations. "Related stocks were also hit. WH Smith - purveyor of overpriced sweets and Evian - slipped down the board as a result. Apart from the immediate damage this will do at the height of the school holidays and peak summer season, the quarantine decision also underlines the inherent risk you take in booking a holiday abroad right now, which will do nothing for consumer confidence," Wilson added.

----------

Domino's Pizza, down 5.5%. Citigroup downgraded the pizza delivery chain to Sell from Neutral.

----------

OTHER MAIN MARKET AND AIM - WINNERS

----------

Verona Pharma, up 28%. The pharmaceutical company said the impact of Covid-19 on clinical trials in the first half has been limited, and the company remains on track to start its Phase 3 clinical trials with Ensifentrine for the treatment of chronic obstructive pulmonary disease later in 2020. The company also said it has received a notice from US Food & Drug Administration to proceed with a study of Ensifentrine in patients with Covid-19. The company plans to initiate a randomized, double-blind, placebo-controlled pilot clinical study to evaluate Ensifentrine delivered via pressurized metered-dose inhaler formulation as a treatment for patients hospitalized with Covid-19 at the University of Alabama. The study is expected to start in the third quarter of 2020. Ensifentrine is an investigational inhaled therapy that has been shown to act as both a bronchodilator and an anti-inflammatory agent in one compound.

----------

Bluejay Mining, up 12%. The miner said it completed a final public consultation meeting as part of its attempts to ink an exploitation licence for a project in Greenland. The public consultation for the Dundas ilmenite project was previously hit with delays. Due to Covid-19 affecting consultation meetings, the government of Greenland extended the consultation period from eight to 10 weeks, Dundas said in June. And in July, Bluejay had agreed an offtake deal with a "multinational commodity trading firm" at Dundas increased. The new agreement increased the amount of ilmenite to between 250,000 and 300,000 tonnes per year, extending agreement by three months to October 31.

----------

Quiz, up 8.0%. The fashion retailer said it has secured an increase and extension to its existing loan facilities from lender HSBC. The clothing company's total bank facilities has been doubled to GBP3.5 million from GBP1.8 million, comprising an overdraft facility of GBP2.0 million and a working capital facility of GBP1.5 million. The loans will remain in place until the end of October. There are no financial covenants applicable to the facilities. Quiz, which has been hammered by the Covid-19 lockdown, has GBP5.7 million in cash in addition to the loan facilities.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
7 Mar 2019 11:28

DIRECTOR DEALINGS: Verona Pharma Chair David Ebsworth Buys Shares

LONDON (Alliance News) - Clinical-stage biopharmaceutical company Verona Pharma PLC said on Thursday Chair David Ebsworth bought 26,300 shares for 56.30 pence each on Wednesday.Following in

Read more
4 Mar 2019 13:35

Monday broker round-up

(Sharecast News) - RSA Insurance Group: JP Morgan downgrades to neutral with a target price of 610p.

Read more
4 Mar 2019 10:12

Verona Pharma Reports Positive Data From Lung Disease Treatment Trial

LONDON (Alliance News) - Shares in Verona Pharma PLC rose on Monday following positive data from part of a Phase Two clinical trial of a dry powder inhaler formulation of Verona's ensifentrine

Read more
14 Jan 2019 10:23

WINNERS & LOSERS SUMMARY: JD Sports Rises After Strong Christmas

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - LOSERS----------Paddy Power

Read more
14 Jan 2019 09:47

Verona Pharma's Ensifentrine COPD Study Does Not Meet Primary Endpoint

LONDON (Alliance News) - Verona Pharma PLC on Monday said its phase two clinical trial of nebulized Ensifentrine did not meet its primary endpoint but did perform better than placebo.Shares

Read more
14 Jan 2019 08:48

Verona Pharma shares plunge on latest drug trial results

(Sharecast News) - Verona Pharma shares were well into the red on Monday, after the clinical-stage biopharmaceutical company announced top-line data from its latest trial of RPL554, failing to reach its primary endpoint.

Read more
9 Jan 2019 15:44

Verona Pharma granted WHO approval for Ensifentrine name

(Sharecast News) - Clinical stage biopharmaceutical outfit Verona Pharma has been granted approval of the name Ensifentrine for its first-in-class, inhaled, dual inhibitor drug candidate RPL554 by the World Health Organisation.

Read more
17 Dec 2018 14:22

Verona Pharma initiates Phase 2 study of RPL554

(Sharecast News) - Clinical-stage biopharmaceutical company Verona Pharma announced the initiation of a Phase 2 clinical trial to evaluate the pharmacokinetic (PK) profile, efficacy and safety of a dry powder inhaler (DPI) formulation of 'RPL554', in patients with moderate to severe chronic obstructive pulmonary disease (COPD), on Monday.

Read more
6 Nov 2018 11:56

Verona Pharma Third-Quarter Loss Narrows On Finance Income

LONDON (Alliance News) - Verona Pharma PLC on Tuesday said its loss narrowed by two thirds in the third quarter of 2018 on increased finance income and reduced costs as it initiated a phase two of

Read more
31 Oct 2018 12:25

Verona Pharma Completes Enrollment In Clinical Trial Of RPL554

LONDON (Alliance News) - Verona Pharma PLC said Wednesday it has completed the enrollment for its Phase 2 clinical trial evaluating the effect of nebulised RPL554 as an add-on to dual therapy in a

Read more
26 Oct 2018 11:46

Verona Pharma turns in positive data from RPL554 trials

(Sharecast News) - Clinical-stage biopharmaceutical company Verona Pharma turned in some positive data from its pre-clinical and Phase 2a trials on its potential cystic fibrosis treatment RPL554.

Read more
1 Aug 2018 12:49

Verona Pharma Starts Phase 2 Trial For Respiratory Disease Treatment

LONDON (Alliance News) - Verona Pharma PLC said Wednesday that it started the second phase of a clinical trial of its nebulized RPL554 drug for the treatment of patients with chronic obstructive 2

Read more
8 May 2018 07:01

LONDON MARKET EARLY CALL: Stocks Called Lower As Iran Fears Boost Oil

LONDON (Alliance News) - Stock prices in London are seen opening lower on Tuesday following Monday's UK bank holiday as Chinese exports recovered at a faster pace in April amid concerns the US

Read more
26 Mar 2018 10:19

Verona Pharma Shares Rise As It Gets Good Results From RPL554 Trials

LONDON (Alliance News) - Verona Pharma PLC said Monday it has received positive top-line data from its phase 2b study for its proposed RPL554 treatment.RPL554 is a for

Read more
8 Mar 2018 13:59

DIRECTOR DEALINGS: Verona Pharma CEO Karlsson Buys 3,250 Shares

LONDON (Alliance News) - Verona Pharma PLC, a clinical-stage biopharmaceutical company, said Thursday that Chief Executive Officer Jan-Anders Karlsson purchased 3,250 ordinary

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.